Business
License agreement for LPLDL®
License agreement for LPLDL®.
About this update from Optibiotix Health Plc
[{"type":"text","content":"\n \nRNS Number : 4420Z OptiBiotix Health PLC 20 May 2019 \n\nOptiBiotix Health plc\n(\"OptiBiotix\" or the \"Company\")\n \nLPLDL® license agreement for new application in hypertension\n \nOptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, cardiovascular disease and diabetes, announces that its fully-owned subsidiary ProBiotix Health Ltd. (\"ProBiotix\"), has signed a license agreement with Nutrilinea Srl. (\"Nutrilinea\") for the use of LPLDL® in a food supplement for the reduction of high blood pressure (hypertension). Nutrilinea will cover the cost of all product development, manufacturing and human studies in return for 12 months exclusivity for the European market. ProBiotix has exclusivity for the UK and all other markets outside Europe.\n \nNutrilinea, based near Milan in northern Italy, is a manufacturer of food supplement formulations containing probiotics, with over 15 years' experience in the development of products for the food and pharmaceutical industries in Europe and the United States. It is one of OptiBiotix's preferred manufacturers, and currently produces the Company's CholBiome®, CholBiome®x3 and SlimBiome® Medical products. Nutrilinea has technology that enables the production of multilayer tablets used in CholBiome®x3 which will also be used for this new product. In an independent human study by the University of Reading, there was a statistically significant reduction in both blood pressure and cholesterol in volunteers taking LPLDL® compared to a control group (Costabile et al., 2017). The European Cardiovascular Society reported in 2016 that the combination of lowering LDL cholesterol and systolic blood pressure has the potential to \"dramatically reduce\" a person's lifetime risk of cardiovascular disease.\n \nHypertension is a global healthcare issue and is one of the strongest risk factors for almost all cardiovascular diseases. The fact that it does not have obvious symptoms have lead doctors to call hypertension a 'silent killer'. Studies conducted in Europe and in the United States suggest that, under new hypertension guidelines, a large percentage of the adult population may be considered hypertensive: some 14 million people in the UK and over 100 ...